The GLP-1 agonist at the center of Pfizer’s upfront $4.9 billion buyout of Metsera last week has been tied to 14.1% weight loss at 28 weeks as well as “potentially class-leading tolerability,” ...

Pfizer is facing a landmark lawsuit in the US brought on behalf of more than 1,000 women who say they developed brain tumors after taking the popular contraceptive injection Depo-Provera. On Monday, ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

July 24 (Reuters) - Pfizer's (PFE.N), opens new tab gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and ...

Pfizer signed a deal with the White House to help Americans pay lower prices for prescription drugs. This agreement removes the uncertainty hanging over Pfizer's head related to the Trump ...

Aug 15 (Reuters) - In the latest setback for Pfizer's (PFE.N), opens new tab sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal in a late-stage trial for patients ...

Pfizer may be one of the biggest bargains in the market today. The drugmaker offers an attractive yield, a rock-bottom valuation, and an underappreciated cancer pipeline. Long-term investors shouldn't ...